DOCKET NO.: C1037.70042US0

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Arthur M. Krieg

Serial No.:

10/613524

Confirmation No.:

4728

Filed:

July 3, 2003

For:

NUCLEIC ACID COMPOSITIONS FOR STIMULATING IMMUNE

RESPONSES

Examiner:

Oluwatosin Gisanrin

Art Unit:

1645

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, day of July, 2006.

Sharon R. Story

Commissioner For Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Transmitted herewith are the following documents:

- Preliminary Amendment
- Substitute Sequence Listing with Identical Computer Readable Diskette
- Statement Pursuant to 37 C.F.R. 1.821(f) and 1.825(a) and (b)
- Copy of Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures
- Return Receipt Postcard

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 646-8000, Boston, Massachusetts.

A check is not enclosed. If a fee is required, the Commissioner is hereby authorized to charge Deposit Account No. 23/2825. A duplicate of this sheet is enclosed.

> Respectfully submitted, Arthur M. Krieg, Applicant

By:

Maria A. Trevisan, Reg. No.: 48,207 Wolf, Greenfield & Sacks, P.C.

600 Atlantic Avenue


Boston, Massachusetts 02210-2206

Telephone: (617) 646-8000


Docket No.: C1037.70042US00 Date: July 24, 2006

x07/22/06x

10525441



Please find below and/or attached an Office communication concerning this application or proceeding.





United States Patent and Trademark Office

JUL 2 7 2006

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, DC 2023I
WWW.USDIO.GOV

APPLICATION NO./CONTROL NO. 10/613,524

SILING DATE

FIRST NAMED INVENTOR /PATENT IN REEXAMINATION

ATTORNEY DOCKET NO.

EXAMINER

Robert A. Zeman

ART UNIT

PAPER

1645

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

APPLICANT IS GIVEN ONE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.F.R.. §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Robert A. Zeman whose telephone number is (571) 272-0866.

ROBERT ZEMAN PATENT EXAMINER